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Water-soluble, stable and azide-reactive strained dialkynes for 
biocompatible double strain-promoted click chemistry 
Krishna Sharma,a Alexander V. Strizhak,a Elaine Fowler,a Xuelu Wang,b Wenshu Xu,c Claus Hatt 
Jensen,a Yuteng Wu,a Hannah F. Sore,a Yu Heng Lau,*,d Marko Hyvönen,*,b Laura S. Itzhaki,*,c David 
R. Spring*,a  
The Sondheimer dialkyne is extensively used in double strain-promoted azide-alkyne cycloadditions. This reagent suffers 
with poor water-solubility and rapidly decomposes in aqueous solutions. This intrinsically limits its application in biological 
systems, and no effective solutions are currently available. Herein, we report the development of novel highly water-soluble, 
stable, and azide-reactive strained dialkyne reagents. To demonstrate their extensive utility, we applied our novel dialkynes 
to a double strain-promoted macrocyclisation strategy to generate functionalised p53-based stapled peptides for inhibiting 
the oncogenic p53-MDM2 interaction. These functionalised stapled peptides bind MDM2 with low nanomolar affinity and 
show p53 activation in a cellular environment. Overall, our highly soluble, stable and azide-reactive dialkynes offer significant 
advantages over the currently used Sondheimer dialkyne, and could be utilised for numerous biological applications.
Introduction
Strain-promoted azide-alkyne cycloaddition (SPAAC) reactions 
are widely employed for covalent modification of biomolecules 
in living systems.1 These utilise a high-energy, strained 
cyclooctyne molecule as the reaction driving force, thus 
avoiding the use of cytotoxic copper catalysts employed in 
copper(I)-catalysed azide-alkyne cycloadditions (CuAAC).2-4
A double SPAAC has been developed using Sondheimer 
dialkyne 1, which contains two strained alkyne moieties both 
able to undergo SPAAC reactions (Figure 1a).5, 6 The use of a 
double-strained dialkyne reagent enables efficient conjugation 
of two azide containing molecules in a metal-free environment. 
The Sondheimer dialkyne has been used for a range of 
applications, including the macrocyclisation of bis-azide 
functionalised peptides,7-12 chemical modification of azido-
proteins in cells,5 post-synthetic modification of metal-organic 
framework thin films,13 tetramerisation of HIV-related 
peptides,14 and for the preparation of fluorescent dyes.15 
Notably, these dialkynes are fundamentally limited in their 
biological application due to inherently poor water-solubility 
and aqueous stability (τ1/2 ∼ 10 min at pH = 7.4).16, 17 
Following the introduction of SPAAC there has been a 
considerable amount of research towards the development of 
new water-soluble, stable, and azide-reactive strained 
cyclooctyne based reagents. Highly reactive strained alkyne 
reagents allow probing of fast biological processes and enable 
reactions in biological systems at low reagent concentrations. 
As a result, numerous derivatives of strained cyclooctyne 
molecules which exhibit either improved water-solubility, 
stability or azide-reactivity have been synthesised and applied 
to SPAAC in vitro and in vivo.18-21 However, research has been 
less successful towards the development of water-soluble, 
stable and azide-reactive dialkyne reagents, despite their 
extensive utility.22 
a.Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge 
CB2 1EW, United Kingdom.
b.Department of Biochemistry, University of Cambridge, 80 Tennis Court Road, 
Cambridge CB2 1GA, United Kingdom.
c. Department of Pharmacology, University of Cambridge, Tennis Court Road, 
Cambridge CB2 1PD, United Kingdom.
School of Chemistry, Eastern Ave, The University of Sydney, NSW 2006, Australia
Electronic Supplementary Information (ESI) available: [details of any supplementary 
information available should be included here]. See DOI: 10.1039/x0xx00000x
(a) Previous work
N3
N3 N
N
N N
N
N
1
Sondheimer dialkyne
N
N+
CF3COO-
(b) This work
28
Potent MDM2 inhibiting stapled peptide
Kd = 7 nM
Cellular activity observed
PDI-E
26
22
Double SPAAC reagent:
- Low aqueous solubility
- Poor aqueous stability
Our improved double SPAAC reagent:
- High aqueous solubility
- High aqueous stability
N
N+
CF3COO-
Ac LTF N
H
C
O
EYWAQL
N3
N
H
C
O
N3
S NH2 Ac LTF NH
C
O
EYWAQL N
H
C
O
S NH2
N+
N
CF3COO-
N
N
N
N
N
N
Page 1 of 5 Organic & Biomolec lar Chemistry
O
rg
an
ic
&
B
io
m
ol
ec
ul
ar
C
he
m
is
tr
y
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
09
 A
ug
us
t 2
01
9.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f C
am
br
id
ge
 o
n 
8/
9/
20
19
 2
:1
0:
22
 P
M
. 
View Article Online
DOI: 10.1039/C9OB01745C
ARTICLE Journal Name
2 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx
Please do not adjust margins
Please do not adjust margins
Figure 1. a) Previous work: development of the Sondheimer dialkyne for double 
strain-promoted azide-alkyne cycloaddition (SPAAC). b) This work: development 
of a highly water-soluble and stable, strained dialkyne reagent and an example of 
its application in the generation of p53-MDM2 inhibiting stapled peptides. 
Scheme 1. a) Synthesis of benzyl sulfone substituted aldehyde substrates. b) 
Synthesis of substituted dialkynes.
In this work, we report the synthesis of water-soluble, 
stable, and azide-reactive strained dialkyne reagents which 
address these limitations. Meta-trimethylammonium 
substituted Sondheimer dialkyne 22 exhibited high water-
solubility, excellent stability and high azide-reactivity (Figure 
1b). Finally, these dialkynes were applied to a double strain-
promoted macrocyclisation strategy7 to generate functionalised 
p53-based stapled peptides which inhibit the oncogenic p53-
MDM2 interaction (Figure 1b).
Results and discussion
Novel nitro and amine substituted dialkynes were designed to 
improve the physical characteristics of these reagents. The 
substitutions were made at the ortho- and meta- positions 
relative to the alkyne moiety based on Orita’s synthetic route.22, 
23 The ortho-nitro and meta-nitro substituted sulfones 8 and 9 
were synthesised by subjecting commercially available nitro 
substituted arenes 2 and 3 to Wohl-Ziegler bromination, 
followed by nucleophilic substitution with benzenesulfinic acid 
sodium salt (Scheme 1a). The resulting benzyl sulfones 4 and 5 
were subjected to DIBAL-H reduction followed by Dess-Martin 
oxidation to deliver the desired benzyl sulfone aldehyde 
substrates 8 and 9. Reduction of the nitro-group in sulfones 4 
and 5, followed by reductive methylation afforded dimethyl 
substituted anilines 12 and 13.24, 25 DIBAL-H reduction followed 
by Dess-Martin oxidation26 gave the desired ortho- and meta-
dimethylamine substituted substrates 16 and 17.
Figure 2. Predicted (clogP) water-solubility values of substituted dialkynes 20-25. 27 
Experimentally determined (logP) values and second-order rate constants (k, in M-1 s-1) 
indicated below. 
Substrates 16 and 17 were then transformed to the 
respective cyclic diacetylenes through double elimination.23 
These substrates were then subjected to Wittig-Horner 
conditions in the presence of LiHMDS and diethyl 
chlorophosphate to form the cyclised intermediates 18 and 19 
in 15 and 26% respective yields, which were finally treated with 
LDA to eliminate the two phenylsulfonyl groups, affording the 
desired substituted strained dialkynes 20 and 21 in moderate 
yields (Scheme 1b). When this protocol was applied to nitro-
substituted aldehydes 8 and 9 the Wittig-Horner conditions 
were unsuccessful, and no product was formed.
To further improve their physical properties, dimethylamine 
substituted dialkynes 20 and 21 were treated with methyl 
trifluoromethanesulfonate in dichloromethane to give 
trimethylammonium substituted dialkynes 22 and 24 (see SI 2.1 
for details).28 The dialkynes 22 and 24 were further methylated 
in acetonitrile to deliver bis-ammonium dialkynes 23 and 25. 
Gratifyingly, all of the trimethylammonium substituted 
dialkynes 22-25 were found to be readily soluble in water 
thereby overcoming this limitation. Water-solubility of meta-
substituted bis-ammonium dialkyne 23 was determined 
experimentally by measuring its octanol-water partition 
coefficient using the shake-flask method,29 which 
demonstrated 23 (logP = -1.50) to be more soluble than the 
uncharged dialkyne 20 (logP = 1.11), which was consistent with 
predicted solubility trends (Figure 2). 
Next, the aqueous stability of these highly water-soluble 
trimethylammonium substituted dialkynes 22 and 23 was 
investigated. Dialkynes 22 and 23 were subjected to aqueous 
buffer conditions (1 mM in PBS, pH 7.4, r.t.) and decomposition 
was monitored by UV spectroscopy (see SI 2.3 for details). We 
observed no decomposition of 22 nor 23 even after 7 days. 
Under the same conditions, Sondheimer dialkyne 1 is known to 
have a decomposition half-life of 10 ± 2 minutes.16 Moreover, 
23 when stored neat at r.t. did not show any decomposition 
after two weeks, whereas the Sondheimer dialkyne completely 
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decomposes within two days.16 We believe that these dialkynes 
will exhibit similar stability to thiols as Sondheimer dialkyne.
We also investigated the azide-reactivity of these amine 
substituted dialkynes 20-25 in a SPAAC, with benzyl azide as a 
model substrate in methanol. We studied the reaction kinetics 
by monitoring the consumption of dialkynes 20-25 using UV 
spectroscopy and measured their second-order rate constants 
(see SI 2.10 for details). The second-order rate constants 
determined experimentally are depicted in figure 2. We 
observed that the substitution of a single dimethylamine 
substituent at the meta-position in 20 with a charged 
trimethylammonium substituent (22, 0.097 M-1s-1) led to a 2.5-
fold increase in the rate when compared to 20. Installation of 
another trimethylammonium substituent at meta-position in 22 
(23, 0.174 M-1s-1) pleasingly led to a further 1.8-fold increase in 
the rate over dialkyne 22. However, presence of a 
dimethylamine or trimethylammonium substituent at the 
ortho-position (21, 24, and 25) led to a significant decrease in 
the rate of reaction, making them essentially unreactive 
towards benzyl azide at rt (see SI Figure S2.10). Overall, 
trimethylammonium substituted 22 and 23 were found to be 
the most reactive dialkynes. We believe that the high azide-
reactivity of 22 and 23 stems from the electronic effect of the 
charged trimethylammonium substituent which potentially 
lowers the transition state barrier required for SPAAC with 
azide, as has been reported previously with BARAC in the 
presence of a fluoro substituent.30 The poor reactivity of ortho-
substituted 21, 24, and 25 is attributed to the steric effects of 
bulky dimethylamine/trimethylammonium substituent.
With substituted Sondheimer dialkynes 20-25 in hand, we 
investigated their application in stapling phage display peptide 
PDI-E 26 (Ac-LTFXEYWAQLXS-NH2, X=Orn(N3)) for targeting the 
oncogenic p53-MDM2 interaction.31, 32 The p53 protein is a 
transcription factor and tumour suppressor. Its activity is 
inhibited by interaction with the E3 ligase MDM2, which is 
overexpressed in many cancers and targets p53 for 
proteasome-mediated degradation.33 The stapling of peptide 
26 with Sondheimer dialkyne 1 has been previously shown by 
our group to be a potent inhibitor of the p53-MDM2 
interaction.7 Stapling reactions between peptide 26 and 
dialkynes 20, 22, and 23 successfully gave the stapled peptides 
27-29 in 25-36% yields within 24 h (Scheme 2).34 Ortho-
substituted dialkynes 21, 24, and 25 were found to be 
unreactive under the reaction conditions.
Scheme 2. Application of substituted Sondheimer dialkynes in double strain-promoted 
macrocyclisation strategy to generate functionalised stapled peptides for p53-MDM2 
inhibition. The yields depicted are the isolated yields of the major fraction of the stapled 
peptides obtained after HPLC purification. The major isomer of functionalised stapled 
peptides separated by HPLC purification were tested for biological activity.
Functionalised stapled peptides 27-29 were then tested in a 
competitive fluorescence polarisation (FP)35, 36 assay for MDM2 
binding affinity (see SI 2.8 for details). Stapled peptide 28 which 
contained one trimethylammonium substituent, was found to 
exhibit the highest binding affinity (7.0  3.9 nM). Installation of 
a second trimethylammonium group on the dialkyne caused a 
slight reduction in the binding affinity (29, 17.0  6.2 nM). 
A crystal structure of MDM2 complexed with meta-
trimethylammonium functionalised peptide 28 was obtained to 
help determine whether the charged trimethylammonium 
group interacts with the protein (17-108, E69A/K70A;37 Figure 
3). Previous studies have shown that the staple moiety of the 
peptide can interact with the protein.7, 38-41 The MDM2-bound 
stapled peptide 28 was shown to be in an α -helical 
conformation as expected, with the binding triad (F3, W7, L10) 
in the correct orientation to engage the respective binding 
hotspots on MDM2 (Figure 3: Top view).7 Two MDM2-bound 
peptide molecules were observed in one asymmetric unit, with 
the staple moiety shifted away from the MDM2 surface due to 
the charged trimethylammonium group (see SI Figures 
S2.7.1.3.1a and S2.7.1.3.1b). The bis(triazolyl) staple of the 
bound peptide 28 exists as the anti regioisomer with the 
charged trimethylammonium group pointing away from MDM2 
surface (Figure 3: Side view). 
Next, we tested the ability of functionalised stapled 
peptides 27-29 to inhibit the p53-MDM2 interaction in an 
established p53 reporter cell-based assay.36 We treated p53 
reporter cells with linear peptide 26 and dialkynes 1, 20, 22, and 
23 in a 96-well format (Figure 4). In situ parallel stapling with 
multiple substituted dialkynes provides a faster way of 
screening resultant stapled peptides directly in the cellular 
medium, without performing individual stapling reactions and 
purifications for each dialkyne variant.7,42 p53 activation values 
are reported as fold activation over the activation value 
obtained when cells were treated with 1% DMSO. This provides 
an indirect comparative measure of the cellular p53 levels 
where higher values are indicative of increased cellular activity. 
We also tested the corresponding purified stapled peptides 27-
29 in this assay which confirmed the potencies (see SI 2.9 for 
details). Peptide 29 gave a negligible response in this assay, 
most likely due to cell permeability issues with the doubly 
charged dialkyne. Peptide 28 was able to permeate the cell and 
gave 1.7-fold activation of p53. We feel that the advantages in 
usability of our water-soluble, stable and azide-reactive 
dialkynes make these reagents a substantial improvement over 
the Sondheimer dialkyne.
Top View Side View
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Figure 3. Crystal structure of 28 bound to MDM2 at 2.0 Å resolution (PDB ID: 6H22). Top 
and side views depicting the bound stapled peptide 28 in -helical conformation and the 
staple as anti regioisomer (only the staple and side chains of the three binding residues 
are shown for clarity). The 2Fo-Fc electron density map is contoured at 1. 
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O
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O
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R1
R2
Substituted dialkynes 
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p53 reporter cells
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Figure 4. p53 activation in a cellular reporter assay for in situ stapling of peptide 26 (50 
M) with substituted dialkynes 20, 22, 23 and dialkyne 1 (0.5 mM) in parallel, giving 
stapled peptides 27, 28, 29, and 30 respectively (performed as technical triplicate). Data 
reported as fold activation over 1% DMSO. DMEM- Dulbecco’s Modified Eagle’s Medium.
Conclusions
In conclusion, substituted strained dialkyne reagents have been 
synthesised for biocompatible double strain-promoted click 
chemistry. These highly azide-reactive novel dialkyne reagents 
were shown to be both water-soluble and stable under aqueous 
conditions. To demonstrate their extensive utility, we applied 
these dialkynes to an in situ double-strain promoted 
macrocyclisation strategy to generate functionalised stapled 
peptide inhibitors of the oncogenic p53-MDM2 interaction. 
These stapled peptides were all shown to bind MDM2 with low 
nanomolar affinity by FP assay. Furthermore, the structure of 
our MDM2-bound functionalised stapled peptide 28 was 
elucidated through X-ray crystallography, which confirmed the 
α-helical conformation of the peptidic backbone, and indicated 
the staple moiety was shifted away from the MDM2 surface. 
Peptide 28 was found to permeate the cell and gave 
comparable biological data to the unsubstituted dialkyne. These 
water-soluble, stable and azide-reactive strained dialkyne 
reagents could be successfully applied to numerous 
therapeutically relevant protein-protein interactions and 
conjugation applications.
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